Mij
Senior Member (Voting Rights)
Vibrant Study
Encouraged by these discoveries and preclinical data, Suh launched a first-in-human clinical trial. In this pilot study called VIBRANT—Validating Benefits of Rapamycin for Reproductive Aging Treatment—50 healthy reproductive-age women were enrolled. Half received rapamycin weekly for three months. All participants were then monitored for nine months.
“We received over 200 emails from women eager to enroll when the study went live,” Suh recalled.
This first VIBRANT trial served as a proof-of-concept: it aimed to test the safety and feasibility of short-term rapamycin use and its potential effects on ovarian function. The drug was well tolerated, with no significant adverse events, and some participants reported unexpected benefits like improved memory and overall well-being.
One possible mechanism is that rapamycin reduces the number of follicles activated each month—effectively preserving the ovarian reserve and potentially delaying reproductive aging. Building on this foundation, the next phase—VIBRANT II—will expand to a multi-center trial enrolling about 200 women.
LINK
Encouraged by these discoveries and preclinical data, Suh launched a first-in-human clinical trial. In this pilot study called VIBRANT—Validating Benefits of Rapamycin for Reproductive Aging Treatment—50 healthy reproductive-age women were enrolled. Half received rapamycin weekly for three months. All participants were then monitored for nine months.
“We received over 200 emails from women eager to enroll when the study went live,” Suh recalled.
This first VIBRANT trial served as a proof-of-concept: it aimed to test the safety and feasibility of short-term rapamycin use and its potential effects on ovarian function. The drug was well tolerated, with no significant adverse events, and some participants reported unexpected benefits like improved memory and overall well-being.
One possible mechanism is that rapamycin reduces the number of follicles activated each month—effectively preserving the ovarian reserve and potentially delaying reproductive aging. Building on this foundation, the next phase—VIBRANT II—will expand to a multi-center trial enrolling about 200 women.
LINK